Pharmako receives TGA approval for its manufacturing facility
Pharmako Biotechnologies, the sister company of Gencor in the U.S., received approval from the Therapeutic Goods Administration (TGA), Department of Health and Aging for the Government of Australia, for its manufacturing facility.
Photo © iStockphoto.com/volk65
Pharmako Biotechnologies (N.S.W., Australia), the sister company of Gencor in the U.S., received approval from the Therapeutic Goods Administration (TGA), Department of Health and Aging for the Government of Australia, for its manufacturing facility. Pharmako is now a licensed manufacturer for the production of active pharmaceutical ingredients (APIs) with advanced dispersion and solubility technologies, including its pre-mixes, capsules, liquids and powders.
“We are pleased to have received TGA approval for our facility in Australia,” said Eric Meppem, co-founder and commercial director, Pharmako, in a press release. “Given the stringent requirements of the TGA for the manufacturing of APIs, we feel even more confident in our ability to exceed the quality assurance demands of our customers.”
“The granting of this license reflects the level of dedication and effort from our Quality Team and the entire Pharmako staff,” continued Meppem. “Pharmako proudly exports materials all around the world, and this full license justifies the trust international clients place in the quality of Australian manufacturing.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
